A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia
Sponsor study identifier
Secondary identifiers
interventional
75
1 country
14
Study Start
July 1997
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 2007
Actual (reported)RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory leukemia.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 1997
Date type not reportedThis date has not been verified as actual or estimated.
November 1, 1999
Actual (reported)August 2, 2004
Actual (reported)September 2007
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Advanced Urology Medical Center
Anaheim, California, 92801, United States
South Coast Urological Medical Group
Laguana Hills, California, 92653, United States
Urology Specialists, P.C.
Waterbury, Connecticut, 06708, United States
Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center
Sarasota, Florida, 34239, United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637, United States
206 Research Associates
Greenbelt, Maryland, 20770, United States
Mid Atlantic Clinical Research
Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, Kamen BA. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2008 Jun;62(1):65-75. doi: 10.1007/s00280-007-0576-7. Epub 2007 Sep 2.
Barton A. Kamen, MD, PhD
Rutgers Cancer Institute of New Jersey
First Submitted
November 1, 1999
First Posted
August 2, 2004
Study Start
July 1997
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
September 2007
Actual (reported)CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Rockville, Maryland, 20850, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
Medical & Clinical Research Associates, LLC
Bay Shore, New York, 11706, United States
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
Medical City Dallas Hospital
Dallas, Texas, 75230, United States
Urology Centers of North Texas
Dallas, Texas, 75231, United States
Urology San Antonio Research
San Antonio, Texas, 78229, United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105, United States
Last Updated
January 6, 2014
Record last verified: 2008-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: